A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

May 29, 2024

Study Completion Date

May 29, 2024

Conditions
Mild to Moderate Alzheimer's Disease
Interventions
DRUG

CT1812

Active Study Drug

DRUG

Placebo

Non-active study drug

Trial Locations (32)

3004

Alfred Health, Melbourne

3050

Melbourne Health, Parkville

3079

St Vincent's Hospital Sydney, Ivanhoe

5000

Fundación Neuropolis - Hospital Viamed Montecanal, Zaragoza

6009

Australian Alzheimer's Research Foundation, Nedlands

18600

INEP, Prague

28270

Alzheimer's Memory Center, Charlotte

30100

A-Shine S.R.O, Pilsen

30120

Hospital Clinico Universitario Virgen De La Arrixaca, El Palmar

32159

Charter Research, Lady Lake

32162

Compass Research LLC- Bioclinica Research, The Villages

32751

ClinCloud, LLC, Maitland

32940

ClinCloud, Viera

33155

Allied Biomedical Research Institute, Miami

33462

JEM Research Institute, Atlantis

37005

Centro de Salud San Juan, Salamanca

41009

Hospital Victoria EUGENIA. Unidad de Neurociencias., Seville

44720

Neuro Behavirol Clinical Research C, North Canton

51601

Vestra Clinics, Rychnov nad Kněžnou

85004

21st Century Neurology/ Xenoscience Inc., Phoenix

85258

Imaging Endpoints, Scottsdale

06905

Ki Health Partners, LLC dba New England Institute for Clinical Research, Stamford

43221-3502

The Ohio State University - Wexner, Columbus

628 00

Neuro Health Centrum ltd, Brno

503 41

NeuropsychiatrieHK S.R.O, Hradec Králové

100 00

Clintrial S.R.O, Prague

16 000

Neuropsychiatrie s.r.o., Prague

160 00

Forbeli S.R.O, Prague

5223 LA

Brain Research Den Bosch, 's-Hertogenbosch

1081 GN

Brain Research Center Amsterdam, Amsterdam

8025 AZ

Brain Research Center Zwolle, Zwolle

08028

Fundación ACE, Barcelona

Sponsors
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Cognition Therapeutics

INDUSTRY

NCT03507790 - A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. | Biotech Hunter | Biotech Hunter